Core Viewpoint - The recent news about Jibeier, a company listed on the Sci-Tech Innovation Board, highlights the upcoming submission of its new antidepressant drug JJH201501 for market approval, alongside the strong performance of its existing products, Likujun tablets and Nigulol tablets, which is generally seen as a positive development [1] Group 1: Company Performance and Market Perception - Despite the positive performance of Jibeier's products, it is emphasized that good current performance does not guarantee future stock price increases, as market perceptions can often overshadow actual performance [3] - The true determinant of stock price movements is not merely the surface performance metrics but rather the real attitudes of institutional investors towards the stock [4] - Historical data shows that during various market phases, a significant number of stocks fail to outperform the market index, indicating that merely holding good companies does not ensure investment success [6] Group 2: Institutional Investment Insights - The performance of stocks like Anglikang, which has seen significant gains, is attributed to the active participation of institutional investors, highlighting the importance of understanding institutional funding dynamics [9] - A stark contrast is drawn between the institutional participation in Anglikang and another vitamin-related company, Huaheng Biological, illustrating how institutional backing can lead to vastly different stock performances [11] - For Jibeier, the critical question remains regarding the behavior of institutional investors: whether they are accumulating shares or quietly withdrawing, as this will significantly impact the stock's future performance [12] Group 3: Investment Strategy Recommendations - Investors are advised to focus on real trading data rather than just news and financial reports, as actions in the market often speak louder than words [12] - Key recommendations include avoiding being misled by superficial news, learning to interpret data effectively, monitoring the real movements of institutional funds, and establishing a personal quantitative analysis system [12]

Core Viewpoint - The company, Jibeier, is demonstrating strong growth momentum driven by both innovative drug development and the upgrade of traditional products, with significant potential in the market for its existing products and upcoming innovations [1][10]. Group 1: Existing Products - The core product, Likujun Tablets, has undergone a five-year redevelopment process, optimizing its production process and increasing its purity from 94% to over 99.6%, securing two national invention patents valid until December 2041 [2][3]. - Likujun Tablets are widely used in the treatment of conditions associated with low white blood cell counts, with a significant market opportunity as it is now recognized as a recommended drug for malignant tumor treatment [2][3]. - In 2024, Likujun Tablets are expected to achieve sales revenue of 652 million yuan, with only about 20,000 patients currently covered in the tumor market, indicating a vast untapped market potential [3][4]. Group 2: Innovative Drug Pipeline - Jibeier has established three major technology platforms for drug development: deuterated drug research, compound formulation research, and liposome drug research, supporting a series of differentiated innovative drugs [5][6]. - The deuterated drug JJH201501, currently in the data summary phase of its Phase III clinical trial, shows promising results with lower doses achieving effects comparable to mainstream antidepressants, indicating a strong market potential in the antidepressant sector [6][7]. - The company is also developing multiple drugs based on its deuterated technology platform, including JJH201701 for acid reduction and JJH202301 for diabetes, creating a tiered research and development structure [7][8]. Group 3: Sales and Market Strategy - In 2024, the company achieved operating revenue of 897 million yuan and a net profit of 215 million yuan, reflecting a balanced focus on both research and sales [9]. - The company plans to enhance its marketing system and promote its existing products, particularly Likujun Tablets and Niqunlor Tablets, to accelerate sales growth [9][10]. - The Chinese innovative drug sector is currently experiencing a golden period of policy benefits, technological breakthroughs, and market demand, positioning Jibeier favorably for long-term growth [10].

Core Viewpoint - The company, Jibeier, reported a slight revenue growth of 4.14% in 2024, with total revenue of 897 million yuan and net profit of 219 million yuan, indicating a transitional phase after two years of rapid growth due to public health events [1] Financial Performance - In 2024, Jibeier's core product, Likujun tablets, generated 652 million yuan in revenue, remaining stable compared to the previous year, providing strong cash flow support [2] - The company achieved a 41.46% revenue growth for another core product, Nigunluo tablets, reaching 127 million yuan, reflecting successful product diversification efforts [2] - Jibeier plans to distribute a cash dividend of 2.60 yuan per 10 shares, totaling 51.85 million yuan for the year, with cumulative cash dividends expected to reach 155 million yuan, representing 70.58% of net profit [3] Research and Development - Jibeier increased its R&D investment by 26.25% in 2024, totaling 70.41 million yuan, demonstrating confidence in future business growth [4] - The company has established a robust R&D platform focusing on innovative drug development, including compound formulations and deuterated drugs [4] Pipeline and Future Prospects - The most notable pipeline product is the antidepressant JJH201501, which is in phase III clinical trials and expected to complete by the end of 2025, showing promising efficacy and safety [5] - Other pipeline products include JJH201601 for anti-tumor treatment, JJH201701 for acid suppression, and JJH201801 for gallbladder-related conditions, with JJH201601 already in phase IIa trials [5] - Jibeier currently has no export business but is positioned to benefit from improving domestic policies for innovative drugs, potentially expanding its market presence [6]